Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
Status:
Completed
Trial end date:
2020-07-29
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 2 Pilot study to evaluate Disulfiram+Copper Gluconate in patients
metastatic pancreatic cancer whose CA-19-9 levels rise while receiving nab-paclitaxel
(Abraxane) plus gemcitabine (Gemzar) or FOLFIRINOX or single-agent gemcitabine (Gemzar).
Patient must have received a minimum of 8 weeks of treatment and have rising CA-19-9 levels
in the absence of radiographic evidence of progression.